BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17013426)

  • 1. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation.
    Pai SY; DeMartiis D; Forino C; Cavagnini S; Lanfranchi A; Giliani S; Moratto D; Mazza C; Porta F; Imberti L; Notarangelo LD; Mazzolari E
    Bone Marrow Transplant; 2006 Nov; 38(10):671-9. PubMed ID: 17013426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated donor BMT for Wiskott-Aldrich syndrome.
    Lenarsky C; Weinberg K; Kohn DB; Parkman R
    Bone Marrow Transplant; 1993 Aug; 12(2):145-7. PubMed ID: 8401361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
    Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
    Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
    Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies.
    Díaz de Heredia C; Ortega JJ; Díaz MA; Olivé T; Badell I; González-Vicent M; Sánchez de Toledo J
    Bone Marrow Transplant; 2008 Apr; 41(7):627-33. PubMed ID: 18084339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unrelated partially matched peripheral blood stem cell transplantation with highly purified CD34+ cells in a child with Wiskott-Aldrich syndrome.
    Schwinger W; Urban C; Lackner H; Kerbl R; Benesch M; Dornbusch HJ; Sovinz P; Schumm M; Handgretinger R
    Bone Marrow Transplant; 2000 Jul; 26(2):235-7. PubMed ID: 10918439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated bone marrow transplantation in a Wiskott-Aldrich syndrome patient sharing two HLA-extended haplotypes with the donor.
    La Nasa G; Pizzati A; Ledda A; Vacca A; Arras M; Contu L
    Haematologica; 1996; 81(2):178-81. PubMed ID: 8641653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan.
    Kobayashi R; Ariga T; Nonoyama S; Kanegane H; Tsuchiya S; Morio T; Yabe H; Nagatoshi Y; Kawa K; Tabuchi K; Tsuchida M; Miyawaki T; Kato S
    Br J Haematol; 2006 Nov; 135(3):362-6. PubMed ID: 17032176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic cell transplantation for correction of primary immunodeficiencies.
    Filipovich A
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S49-S52. PubMed ID: 18724301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of X-linked polymorphic loci as gene markers to track X allele and chimerism in a post-allogeneic peripheral blood stem cell transplant patient with Wiskott-Aldrich syndrome.
    Sasanakul W; Hongeng S; Chuansumrit A; Chaiyaratana W; Pakakasama S; Hathirat P
    J Med Assoc Thai; 2001 Mar; 84(3):379-84. PubMed ID: 11460939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
    Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the outcomes of allogeneic bone marrow transplantation from partially mismatched related donors, matched sibling donors, and matched unrelated donors in Japanese pediatric patients: a single center result.
    Nagatoshi Y; Kawano Y; Okamura J
    Pediatr Transplant; 2004 Jun; 8(3):260-6. PubMed ID: 15176964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients.
    Lang P; Mueller I; Greil J; Bader P; Schumm M; Pfeiffer M; Hoelle W; Klingebiel T; Heinzelmann F; Belka C; Schlegel PG; Kremens B; Woessmann W; Handgretinger R
    Blood Cells Mol Dis; 2008; 40(1):33-9. PubMed ID: 17884640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
    Sugita J; Tanaka J; Hashimoto A; Shiratori S; Yasumoto A; Wakasa K; Kikuchi M; Shigematsu A; Miura Y; Tsutsumi Y; Kondo T; Asaka M; Imamura M
    Ann Hematol; 2008 Dec; 87(12):1003-8. PubMed ID: 18636260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.